Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

September 25, 2025

Study Completion Date

September 25, 2025

Conditions
Pancreatic NeoplasmsSolid TumorsBiliary Tract CancerLung NeoplasmsBladder Cancer
Interventions
DRUG

brigimadlin

brigimadlin

Trial Locations (60)

106

National Taiwan University Cancer Center, Taipei

2031

Prince of Wales Hospital-Randwick-66496, Randwick

2650

Edegem - UNIV UZ Antwerpen, Edegem

2700

LK Wiener Neustadt, Wiener Neustadt

3010

University Hospital Bern/Inselspital Bern, Bern

3084

Austin Health, Heidelberg

4020

Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz

4101

ICON-South Brisbane-69267, South Brisbane

4126

Rainbow Oncology, KwaZulu

5042

Flinders Medical Centre, Bedford Park

9000

UNIV UZ Gent, Ghent

10016

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

10022

Memorial Sloan-Kettering Cancer Center, New York

11217

Taipei Veterans General Hospital, Taipei

11481

King Abdul Aziz Medical City, Riyadh

11501

Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola

19104

University of Pennsylvania, Philadelphia

20016

Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington D.C.

21079

CTR Georges-François Leclerc, Dijon

28040

Fundación Jiménez Díaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

30625

Medizinische Hochschule Hannover, Hanover

36608

Southern Cancer Center, Mobile

40002

Srinagarind Hospital, Muang

40202

Norton Cancer Institute, Downtown, Louisville

44195

Cleveland Clinic, Cleveland

46010

Hospital Clínico de Valencia, Valencia

48109

University of Michigan Health System, Ann Arbor

60488

Krankenhaus Nordwest, Frankfurt, Frankfurt

68130

Nebraska Cancer Specialists-Omaha-69066, Omaha

77030

The University of Texas MD Anderson Cancer Center, Houston

80124

Rocky Mountain Cancer Centers-Lone Tree-69498, Lone Tree

80756

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

81377

Klinikum der Universität München AÖR, München

85719

University of Arizona, Tucson

89081

Universitätsklinikum Ulm, Ulm

90110

Songklanagarind Hospital, Hat Yai

94305

Stanford Cancer Institute, Palo Alto

94805

INS Gustave Roussy, Villejuif

95403

Providence Medical Foundation-Santa Rosa -69764, Santa Rosa

97239

Oregon Health and Sciences University, Portland

97401

Oncology Associates of Oregon, PC, Eugene

119074

National University Hospital-Singapore-42005, Singapore

404327

China Medical University Hospital, Taichung

90033-9173

University of Southern California, Los Angeles

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

241-8515

Kanagawa Cancer Center, Kanagawa, Yokohama

980-8574

Tohoku University Hospital, Miyagi, Sendai

541-8567

Osaka International Cancer Institute, Osaka, Osaka

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

135-8550

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

755-8505

Yamaguchi University Hospital, Yamaguchi, Ube

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08035

Hospital Universitari Vall D Hebron, Barcelona

CH-1211

University Hospital Geneva, Geneva

WC1E 6AG

University College Hospital, London

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY